GLP-1
PulseAugur coverage of GLP-1 — every cluster mentioning GLP-1 across labs, papers, and developer communities, ranked by signal.
5 day(s) with sentiment data
-
GLP-1 Drugs Boost Women's Employment More Than College Degrees, Study Finds
A study from Harvard University, published by the National Bureau of Economic Research, suggests that GLP-1 drugs, such as Ozempic and Wegovy, have a greater impact on increasing women's employment rates than obtaining …
-
GLP-1 drugs show surprising benefits beyond weight loss
GLP-1 medications, commonly known for weight loss and type 2 diabetes treatment, are demonstrating a range of surprising health benefits beyond their initial applications. Recent trials indicate these drugs can protect …
-
FDA faces decision on popular peptides amid safety and efficacy concerns
The FDA is facing a critical decision regarding the authorization of six popular but experimental peptides, which are increasingly being used for health, fitness, and longevity despite limited scientific evidence. Onlin…
-
South Korean biotech targets 'Ozempic face' with donated fat skin booster
South Korean biotech firm L&C Bio is developing an injectable skin booster derived from donated human fat to address the facial volume loss associated with weight-loss drugs like Ozempic. The product, tentatively named …
-
Medicare launches GLP-1 bridge program for weight loss drugs
The Medicare Bridge program, initiated by the Trump administration, offers eligible seniors and disabled individuals access to certain GLP-1 weight loss medications for a flat $50 monthly co-payment. This demonstration …
-
Wall Street funds boost WuXi AppTec amid soaring weight-loss drug demand
Major Wall Street investment firms, including JPMorgan Chase, UBS, and BlackRock, have significantly increased their stakes in WuXi AppTec, a Chinese pharmaceutical contractor. This surge in investment is driven by the …
-
New breathalyzer accurately measures body fat burning
Researchers have developed a new handheld breathalyzer that accurately measures when the body is burning fat for energy, a state known as ketosis. This device, developed under the supervision of Andreas Güntner, analyze…
-
US healthcare grapples with high GLP-1 costs amid surging demand · 1 source tracked
The U.S. healthcare system faces a significant challenge balancing the high cost of GLP-1 medications with their proven effectiveness in treating chronic diseases like obesity. Spending on these drugs has surged dramati…
-
Obamacare premiums to jump 14% amid rising costs and subsidy expiration
Obamacare premiums are projected to increase by a median of 14% next year, continuing a trend of double-digit hikes. This rise is attributed to escalating healthcare service costs and the expiration of enhanced Affordab…
-
AI drug developer Derui Zhiyao raises $52M for Phase III GLP-1 trial
Derui Zhiyao (德睿智药), an AI-native biopharmaceutical company, has secured $52 million in Series B funding. The capital will be used to enhance its AI drug discovery platform, Molecule Arts Platform (MAP), and advance its…
-
Cigna invests $100M in AI pharmacy program amid specialty drug boom
Cigna's Evernorth is investing $100 million into a new AI-powered pharmacy program, "Pharmacy Forward," aimed at improving clinical care and patient outcomes. This investment is part of a broader trend of significant ca…
-
Cigna's Evernorth invests $100M in AI-powered specialty pharmacy
The Cigna Group's Evernorth division is investing $100 million through 2028 to develop an AI-powered specialty pharmacy program. This initiative, named "Pharmacy Forward," aims to enhance patient access to and experienc…
-
Medicare launches $50/month GLP-1 weight loss drug program
The Trump administration has launched a temporary Medicare Bridge program to provide some beneficiaries with access to popular weight loss medications like tirzepatide and semaglutide for a flat $50 monthly co-payment. …
-
GLP-1 drugs disrupt diet trends, fueling protein-focused food market
GLP-1 medications are fundamentally altering the food industry, according to David Protein CEO Peter Rahal. He states that traditional diet trends are becoming obsolete as people increasingly turn to these drugs for wei…
-
US Summer BBQs Shift Towards Cheaper Proteins Amidst Inflation and GLP-1 Trend
The American summer BBQ is undergoing a subtle transformation driven by persistent food inflation and the growing influence of GLP-1 drugs. While consumers still desire traditional items like burgers, the rising cost of…
-
GLP-1 drugs fuel luxury spending but expose fashion's size inclusivity gap
The luxury sector is experiencing a complex shift influenced by the increasing adoption of GLP-1 weight-loss medications. While overall sector growth has seen a slight dip, these medications are driving consumption as i…
-
Societal interpretations of body fat are shifting due to medical advancements
The interpretation of body fat is evolving due to societal shifts and medical advancements. Historically, being fat was often associated with negative personal traits like laziness or greed, or attributed to genetics. H…
-
UPS invests $48M in temperature-controlled facilities for booming GLP-1 drug deliveries
UPS is investing $48 million to expand its network of temperature-controlled facilities, aiming to capitalize on the growing demand for temperature-sensitive medications like GLP-1 injectables. This strategic move into …
-
Protein popularity surge drives whey protein costs sky-high for snack makers
The increasing popularity of high-protein foods, termed "proteinmaxxing," is driving up the cost of whey protein, a key ingredient for many snack companies. This trend is partly fueled by the use of GLP-1 weight loss dr…
-
GLP-1 weight-loss drugs drive major climate impact by cutting food demand
The widespread adoption of GLP-1 medications for weight loss is having a significant, albeit unintended, impact on the climate by reducing demand for carbon-intensive foods. As more Americans use drugs like semaglutide …